Corporate News & Publications

CLINUVEL's company releases, including archives.

Friday, 15 May 2015 14:00

Media Coverage

Written by
To receive regular updates, including all of CLINUVEL's announcements, you can subscribe to our email database here. A selection of press coverage is listed below Title Link Aus dem Schatten hervortreten NZZ Exposure to sunlight burns my skin – now I can come out the shadows thanks to new drug Bournemouth Echo INTERVIEW: CLINUVEL's Philippe Wolgen on Scenesse and the patient factor Scrip CLINUVEL's subisidiary develops drug candidate for vitiligo Biospectrum Asia Wanneer de zon een hel wordt VTM News Out of the shadows (content only available in the USA) NBC Dateline 11-Year-Old 'Allergic' to Sunlight Good Morning America Implanted…
Singaporean subsidiary VALLAURIX completes preliminary evaluation of VLRX001 SUMMARY Clinuvel expands pipeline with VLRX001 targeting skin disorders First therapeutic target: vitiligo (depigmentation disorder) as maintenance therapy following SCENESSE® (afamelanotide 16mg) Innovation is the result of collaboration between Clinuvel and the international research community Proprietary technology of VALLAURIX PTE LTD, a majority-owned Clinuvel subsidiary Recent clinical research has demonstrated a renaissance in the demand for novel melanocortin molecules Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA: UR9; ADR: CLVLY) today announced that its Singaporean subsidiary VALLAURIX PTE LTD has successfully completed initial in-vitro development of VLRX001, an innovative melanocortin analogue. VLRX001 is an…
Monday, 27 April 2015 15:59

Appendix 4C - Q3 FY15

Tuesday, 31 March 2015 16:59

Clinuvel relocates Melbourne office

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its head office in Melbourne has relocated. The new address, which will also be the Company’s Registered Address, is: Level 5160 Queen StMelbourneVictoria, Australia 3000 All telephone and fax numbers remain the same. - End - About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with…
Friday, 20 March 2015 17:16

Appendix 3B - March 20

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA: UR9; ADR: CLVLY) today announced that its drug SCENESSE® (afamelanotide 16mg) has featured in an editorial in the peer-reviewed Journal of Investigative Dermatology. The editorial – “An α-MSH analogue in erythropoietic protoporphyria” – reviews both Clinuvel’s program and the broader history of the bench to bedside development of α-MSH as a therapeutic drug. In their concluding remarks, the authors note that “[t]he approval of afamelanotide by the European Medicines Agency in late 2014 can be regarded as a breakthrough for α-MSH in clinical medicine.” SCENESSE® was approved under exceptional circumstances by the European Medicines…
Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its vitiligo program will feature in presentations to be given at this week’s American Academy of Dermatology (AAD) 73rd Annual Meeting in San Francisco. Data from Clinuvel’s vitiligo program will be reviewed and discussed by experts involved in the CUV102 and CUV103 clinical trials, where SCENESSE® has been used as a combination repigmentation treatment for darker skinned vitiligo patients. “We are seeing an increasing recognition of the need to treat vitiligo in practical dermatology, which is reflected in the number of presentations featuring Clinuvel’s program,” Clinuvel’s Director, Clinical…
Thursday, 12 March 2015 07:03

Clinuvel Newsletter - March 2015

Friday, 06 March 2015 18:37

S&P Dow Jones Indices Announces March 2015 Quarterly Rebalance of the S&P/ASX Indices

Monday, 02 March 2015 19:30

Appendix 3B - March 2

Quick Links